Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
608
datasets available to search
ShareScore release 0.9.0
Dataset results
608 results for “macular edema”
Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema
ClinicalTrials.gov study NCT00371410. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
ClinicalTrials.gov study NCT03481660. IPD Sharing: YES. Countries: 23. Publications: 0.
Evaluation of RC28-E Injection in Diabetic Macular Edema
ClinicalTrials.gov study NCT04782115. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
ClinicalTrials.gov study NCT03832179. IPD Sharing: NO. Countries: 1. Publications: 11.
Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study)
ClinicalTrials.gov study NCT00468351. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab
ClinicalTrials.gov study NCT03973138. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
ClinicalTrials.gov study NCT00101764. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema
ClinicalTrials.gov study NCT02556424. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema
ClinicalTrials.gov study NCT00369486. IPD Sharing: Not stated. Countries: 0. Publications: 3.
Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation
ClinicalTrials.gov study NCT05138029. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
ClinicalTrials.gov study NCT02302079. IPD Sharing: YES. Countries: 1. Publications: 1.
Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema
ClinicalTrials.gov study NCT04387604. IPD Sharing: NO. Countries: 1. Publications: 3.
Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema
ClinicalTrials.gov study NCT02399657. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Data from: Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion
Objectives: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids for the treatment of macular edema (ME) secondary to central retinal vein occlusion (CRVO). Design: Systematic review and network meta-analysis. Participants: Patients from previously reported randomized controlled trials (RCTs) comparing anti-VEGF and corticosteroids for the treatment of ME secondary to CRVO. Methods: Literature searches were conducted using PubMed, Medline, Embase, Cochrane Library, and clinicaltrials.gov until March 2017. Therapeutic effects were estimated using the proportions of patients gaining/losing ≥15 letters, best-corrected visual acuity (BCVA), and central retinal thickness (CRT). Treatment safety was estimated using the proportions of adverse events, namely increased intraocular pressure (IOP), cataracts, vitreous hemorrhage (VH), and retinal tear. The software ADDIS (version 1.16.8) was used for analysis. Treatment effect and safety of different drugs could be ranked based on simulation. Results: Eleven RCTs comprising 2060 patients were identified. Regarding patients gaining ≥15 letters, aflibercept and ranibizumab were significantly more effective than sham/placebo at 6 months. Regarding patients losing ≥15 letters at 6 months, ranibizumab showed significant improvement compared to dexamethasone. Aflibercept, bevacizumab, or ranibizumab showed greater improvements in BCVA than sham/placebo at 6 months. Intravitreal ranibizumab injection demonstrated greater CRT reduction than both sham and dexamethasone did. Dexamethasone had a higher risk of increased IOP than aflibercept and ranibizumab. Ranibizumab demonstrated a greater risk of cataracts than dexamethasone. Aflibercept and ranibizumab demonstrated low incidence of VH and retinal tear, respectively. Aflibercept had a slight advantage over ranibizumab as assessed by benefit-risk analysis. Conclusions: Anti-VEGF agents have advantages in the treatment of ME secondary to CRVO. Aflibercept and ranibizumab showed marked BCVA improvement and CRT reduction. Aflibercept may have a slight advantage over ranibizumab. The results of this study can serve as a reference for clinicians to provide patient-tailored treatment.
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
ClinicalTrials.gov study NCT01613716. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
ClinicalTrials.gov study NCT04603937. IPD Sharing: NO. Countries: 8. Publications: 0.
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
ClinicalTrials.gov study NCT01476449. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
ClinicalTrials.gov study NCT04976777. IPD Sharing: YES. Countries: 1. Publications: 0.
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
ClinicalTrials.gov study NCT01304706. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
ClinicalTrials.gov study NCT02979665. IPD Sharing: Not stated. Countries: 0. Publications: 5.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.